Payers cover RINVOQ after the trial of 1 TNFi (branded or biosimilar) with 99% preferred combined commercial and Medicare Part D coverage. National Commercial and Medicare Part D formulary coverage under the pharmacy benefit as of January 2025 in RA.
Control that's fast and shown to last.

RA patients met ACR20 at Week 12 or 14 (primary endpoints) and disease control through remission (DAS28-CRP <2.6)* at Weeks 12 or 14 and observed up to 5 years.1-5

RA patients met ACR20 at Week 12 or 14 (primary endpoints) and disease control through remission (DAS28-CRP <2.6)* at Weeks 12 or 14 and observed up to 5 years.1-5

*Clinical remission does not mean drug-free remission or complete absence of disease activity.

Explore the Data

ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria; CRP=C-reactive protein; DAS28-CRP=28-joint disease activity score using C-reactive protein.

aRINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.

bCoverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

INDICATION

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

Rapid Remission1,5

  • Nearly 1/3 of bDMARD-IR patients achieved remission as early as Week 12 (29% RINVOQ 15 mg + csDMARDs [n=164] vs 9% PBO + csDMARDs [n=169] in SELECT-BEYOND)*
See Remission Data at Weeks 12 and 14

Durable Control3,4

  • Remission rates out to 5 years with or without MTX
See Remission Data Up to ~5 Years

Well-Studied Safety1,7

  • >7.5 years max exposure in RA (~4.2 years median) to RINVOQ 15 mg as of 08/2023†
See Safety Profile

Exceptional Patient and Access Support

  • 99% preferred combined national commercial and Medicare Part D formulary coverage under the pharmacy benefit as of January 2025 in RA6,‡,§
  • 1:1 support to help RA patients start and stay on track with their prescribed treatment plan
  • Get patients started on RINVOQ Complete by downloading the enrollment form
Explore Access Information
Learn About Patient Support

*P<0.001. Analyses were not controlled for multiplicity. P-values obtained through nominal statistical testing.5

†In PsA: ~5.7 years maximum exposure (~3.7 years median) to RINVOQ 15 mg as of 08/2023. In AS: ~3.8 years maximum exposure (~1.7 years median) to RINVOQ 15 mg as of 08/2023. In nr‑axSpA: ~3.4 years maximum exposure (~1.1 years median) to RINVOQ 15 mg as of 08/2023.8

‡RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.

§Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

AS=ankylosing spondylitis; bDMARD=biologic disease-modifying antirheumatic drug; csDMARD=conventional synthetic disease-modifying antirheumatic drug; IR=intolerance or inadequate response; max.=maximum; MTX=methotrexate; nr-axSpA=non-radiographic axial spondyloarthritis; PBO=placebo; PsA=psoriatic arthritis; RA=rheumatoid arthritis;

Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.

Learn more about these and the full Important Safety Information below 

RINVOQ (upadacitinib) Met All Primary and Ranked Secondary Endpoints1,8

Primary Endpoint Results (Week 12 or 14)

Primary Endpoint Results (Week 12/14).

*P≤0.001 RINVOQ vs Placebo or MTX, †P=0.0001; Week 1 analyses were not controlled for multiplicity; P‑values obtained through nominal statistical testing.

SELECT-BEYOND (STUDY RA-V):1,9 24-week, randomized, double-blind, placebo-controlled study of 499 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs.

See Study Details

SELECT-EARLY (STUDY RA-I):1,10 48-week, randomized, double-blind, active comparator-controlled study of 947 adult patients with moderate to severe RA who were MTX naïve.

See Study Details

SELECT-MONOTHERAPY (STUDY RA-II):1,2 14-week, randomized, double-blind, active comparator-controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX.

See Study Details

SELECT-NEXT (STUDY RA-III):1,11 12-week, randomized, double-blind, placebo-controlled study of 661 adult patients with moderate to severe RA who had an inadequate response to csDMARDs.

See Study Details

SELECT-COMPARE (STUDY RA-IV):1,12 48-week, randomized, double-blind, active comparator-controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX.

See Study Details
See ACR Response Criteria

ACR=American College of Rheumatology; bDMARD=biologic disease-modifying antirheumatic drug; cMTX=continued methotrexate; csDMARD=conventional synthetic disease-modifying antirheumatic drug; IR=intolerance or inadequate response; MTX=methotrexate; NRI=nonresponder imputation; RA=rheumatoid arthritis; TNFi=tumor necrosis factor inhibitor.